{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:27:12Z","timestamp":1777858032185,"version":"3.51.4"},"reference-count":27,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2015,6,3]],"date-time":"2015-06-03T00:00:00Z","timestamp":1433289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>This study aimed to develop a clinically acceptable method of therapeutic drug monitoring (TDM) for olanzapine and risperidone and to evaluate the feasibility of its implementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>A non-randomised study of inpatients from five Mental Health Trusts was conducted, with a clinical interview at the time of TDM and a subsequent 6-week follow-up review of clinical notes. The TDM intervention comprised: (a) a venous blood sample taken 12 hours post-dose, 7\u201310 days after drug initiation, and (b) rapid results feedback, with interpretation algorithm guidance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Thirty-two participants provided samples (19 prescribed olanzapine, 13 risperidone). Twenty-six participants remained on the target drug at study end, with seven experiencing a dose change, for whom only four of the TDM results were confirmed as having been checked. Mean dose increased for olanzapine (0.9 mg\/day, range 0\u201310) and decreased for risperidone (-0.3 mg\/day, range -4\u20133).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>TDM can be implemented as part of routine clinical practice for both drugs. However, the lack of robust supporting evidence for or against antipsychotic TDM has probably led to a lack of enthusiasm for and interest in the results. Nevertheless, the advent of less invasive measures and the targeting of patients who might be more likely to benefit may facilitate uptake.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0269881115586285","type":"journal-article","created":{"date-parts":[[2015,6,3]],"date-time":"2015-06-03T22:36:20Z","timestamp":1433370980000},"page":"933-942","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Olanzapine and risperidone plasma concentration therapeutic drug monitoring: A feasibility study"],"prefix":"10.1177","volume":"29","author":[{"given":"Suzanne","family":"Law","sequence":"first","affiliation":[{"name":"Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Gudbrandsen","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Magill","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Sweetman","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Rose","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Landau","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J","family":"Flanagan","sequence":"additional","affiliation":[{"name":"Toxicology Unit, King\u2019s College Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony S","family":"David","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxine X","family":"Patel","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2015,6,3]]},"reference":[{"key":"bibr1-0269881115586285","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/19.3.609"},{"key":"bibr2-0269881115586285","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.154.5.672"},{"key":"bibr3-0269881115586285","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000041"},{"key":"bibr4-0269881115586285","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31828b28d5"},{"key":"bibr5-0269881115586285","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3182577c43"},{"key":"bibr6-0269881115586285","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbp116"},{"key":"bibr7-0269881115586285","unstructured":"clinicaltrials.gov. (2014) Parallel group, multiple dose pharmacokinetics study of five antipsychotic medications in psychiatric participants (NCT02087579). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02087579?term=NCT02087579&rank=1 (accessed 25 September 2014)."},{"key":"bibr8-0269881115586285","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1286281"},{"key":"bibr9-0269881115586285","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2013.02.010"},{"key":"bibr10-0269881115586285","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"Frances A","year":"1994","edition":"4"},{"key":"bibr11-0269881115586285","volume-title":"ECDEU Assessment Manual for Psychopharmacology: Revised (DHEW publication number ADM 76\u2013338)","author":"Guy W","year":"1976"},{"key":"bibr12-0269881115586285","doi-asserted-by":"publisher","DOI":"10.3109\/15622975.2012.696143"},{"key":"bibr13-0269881115586285","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1286287"},{"key":"bibr14-0269881115586285","doi-asserted-by":"publisher","DOI":"10.1002\/pst.185"},{"key":"bibr15-0269881115586285","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"bibr16-0269881115586285","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.04.002"},{"key":"bibr17-0269881115586285","first-page":"23","volume":"10","author":"Mangalore R","year":"2007","journal-title":"J Ment Health Policy"},{"key":"bibr18-0269881115586285","volume-title":"CG178","author":"National Institute for Health and Care Excellence","year":"2014"},{"key":"bibr19-0269881115586285","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108091069"},{"key":"bibr20-0269881115586285","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2014.01.014"},{"key":"bibr21-0269881115586285","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318221b408"},{"key":"bibr22-0269881115586285","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(14)70523-7"},{"key":"bibr23-0269881115586285","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.107.042895"},{"key":"bibr24-0269881115586285","volume-title":"Prescribing high-dose and combination antipsychotics: Acute\/PICU, rehabilitation\/complex needs, and forensic psychiatric services (CCQ1125)","author":"Prescribing Observatory for Mental Health","year":"2012"},{"key":"bibr25-0269881115586285","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1993.tb02093.x"},{"key":"bibr26-0269881115586285","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"bibr27-0269881115586285","volume-title":"SF-36 Health Survey Manual and Interpretation Guide","author":"Ware JE","year":"1993"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881115586285","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0269881115586285","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881115586285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:06:23Z","timestamp":1777507583000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0269881115586285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,3]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.1177\/0269881115586285"],"URL":"https:\/\/doi.org\/10.1177\/0269881115586285","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,3]]}}}